Vertex Inc. (VERX)
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Is Vertex Pharmaceuticals Heading to $600?
The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer medicines may add $500 million to revenue this year.
Vertex, Inc. (VERX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Vertex, Inc. (VERX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)
I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic fibrosis franchise. So, in Q4, Trikafta+Kaftrio sales declined 3.1% quarter-on-quarter to about $2.57 billion, missing my "base case" scenario by $45 million.
Vertex: Buy At Ultracheap Multiples, Product Is Safe From AI
Vertex has lost ~70% of its value despite steady growth and margin expansion, creating a compelling buy opportunity. VERX's FY26 guidance targets 10%-11% revenue growth and 23% adjusted EBITDA margin, trading at 2.9x EV/revenue and 12.5x EV/EBITDA. Fears of AI disruption are likely overstated given the complexity and risk of tax compliance, supporting Vertex's defensible niche.
Compared to Estimates, Vertex (VERX) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VERX) Q4 Earnings Match Estimates
Vertex (VERX) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.
Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are eyeing Casgevy and Journavx sales.
Vertex Q4 Earnings Preview: What To Expect This Week
Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Journavx and Casgevy sales remain niche, raising doubts about their ability to drive the next growth phase already priced into consensus. 2026 sales guidance and Q4 Journavx performance are critical; failure to beat expectations may trigger downside risk.
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise
Vertex Pharmaceuticals remains a 'Top Idea' with robust Q3 earnings, a dominant CF franchise, and a broadening late-stage pipeline. VRTX's diversification into pain, kidney, cell, and gene therapies positions it for multiple launches between 2026–2028, supporting long-term growth. Financial strength is evident with $12B in cash, upgraded 2025 revenue guidance ($11.9B–$12B), and accelerating commercial momentum across new franchises.
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand and is advancing into diabetic peripheral neuropathy (DPN) with two phase 3 studies enrolling through 2026. VRTX's BAFF/APRIL inhibitor povetacicept offers a 'pipeline in a pill' approach, targeting IgA Nephropathy and Primary Membranous Neuropathy, with key catalysts ahead and possible expansion opportunities.
